{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:50:26Z","timestamp":1792439426761,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s13730-020-00457-x","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T09:03:36Z","timestamp":1582621416000},"page":"204-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Crescentic IgA nephropathy after administration of human monoclonal interleukin-12\/23p40 antibody in a patient with Crohn\u2019s disease: a case report"],"prefix":"10.1007","volume":"9","author":[{"given":"Nobuhiro","family":"Kanazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5996-8735","authenticated-orcid":false,"given":"Yukihiro","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minako","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuto","family":"Shikida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motonori","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Iyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuho","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"issue":"3","key":"457_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","volume":"16","author":"AR Moschen","year":"2019","unstructured":"Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019;16(3):185\u201396.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"457_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nbt.1903","volume":"29","author":"JM Benson","year":"2011","unstructured":"Benson JM, Sachs CW, Treacy G, Zhou H, Pendley CE, Brodmerkel CM, et al. Therapeutic targeting of the IL-12\/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol. 2011;29(7):615\u201324.","journal-title":"Nat Biotechnol"},{"issue":"9","key":"457_CR3","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.cgh.2017.03.032","volume":"15","author":"R Battat","year":"2017","unstructured":"Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, et al. Association Between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2017;15(9):1427\u201334 (e2).","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"457_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40620-016-0360-z","volume":"30","author":"R Coppo","year":"2017","unstructured":"Coppo R. Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients. J Nephrol. 2017;30(3):339\u201346.","journal-title":"J Nephrol"},{"issue":"2","key":"457_CR5","first-page":"629","volume":"118","author":"H Suzuki","year":"2008","unstructured":"Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008;118(2):629\u201339.","journal-title":"J Clin Invest"},{"issue":"6","key":"457_CR6","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1172\/JCI74475","volume":"124","author":"K Kiryluk","year":"2014","unstructured":"Kiryluk K, Novak J. The genetics and immunobiology of IgA nephropathy. J Clin Invest. 2014;124(6):2325\u201332.","journal-title":"J Clin Invest"},{"issue":"3","key":"457_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.kint.2017.10.019","volume":"93","author":"H Suzuki","year":"2018","unstructured":"Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, et al. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 2018;93(3):700\u20135.","journal-title":"Kidney Int"},{"issue":"8","key":"457_CR8","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1093\/ndt\/gfv221","volume":"30","author":"J Yasutake","year":"2015","unstructured":"Yasutake J, Suzuki Y, Suzuki H, Hiura N, Yanagawa H, Makita Y, et al. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant. 2015;30(8):1315\u201321.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"457_CR9","doi-asserted-by":"publisher","first-page":"e0206865","DOI":"10.1371\/journal.pone.0206865","volume":"13","author":"Y Wada","year":"2018","unstructured":"Wada Y, Matsumoto K, Suzuki T, Saito T, Kanazawa N, Tachibana S, et al. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy. PLoS One. 2018;13(11):e0206865.","journal-title":"PLoS One"},{"issue":"1","key":"457_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10157-018-1582-2","volume":"23","author":"H Suzuki","year":"2019","unstructured":"Suzuki H. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clin Exp Nephrol. 2019;23(1):26\u201331.","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"457_CR11","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","volume":"135","author":"WJ Sandborn","year":"2008","unstructured":"Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al. A randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease. Gastroenterology. 2008;135(4):1130\u201341.","journal-title":"Gastroenterology"},{"issue":"1","key":"457_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/apt.14794","volume":"48","author":"WJ Sandborn","year":"2018","unstructured":"Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, et al. Long-term efficacy and safety of ustekinumab for Crohn\u2019s disease through the second year of therapy. Aliment Pharmacol Ther. 2018;48(1):65\u201377.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"457_CR13","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/oxfordjournals.ndt.a027349","volume":"11","author":"MJ World","year":"1996","unstructured":"World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant. 1996;11(4):614\u201321.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"457_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2215\/CJN.04660513","volume":"9","author":"JM Ambruzs","year":"2014","unstructured":"Ambruzs JM, Walker PD, Larsen CP. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol. 2014;9(2):265\u201370.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"457_CR15","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1172\/JCI20096","volume":"113","author":"J Wang","year":"2004","unstructured":"Wang J, Anders RA, Wu Q, Peng D, Cho JH, Sun Y, et al. Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. J Clin Invest. 2004;113(6):826\u201335.","journal-title":"J Clin Invest"},{"issue":"10","key":"457_CR16","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1056\/NEJMra020109","volume":"347","author":"JV Donadio","year":"2002","unstructured":"Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002;347(10):738\u201348.","journal-title":"N Engl J Med"},{"issue":"3","key":"457_CR17","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1046\/j.1523-1755.2003.00843.x","volume":"63","author":"JC Jennette","year":"2003","unstructured":"Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63(3):1164\u201377.","journal-title":"Kidney Int"},{"issue":"12","key":"457_CR18","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1681\/ASN.2012101017","volume":"24","author":"J Lv","year":"2013","unstructured":"Lv J, Yang Y, Zhang H, Chen W, Pan X, Guo Z, et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol. 2013;24(12):2118\u2013255.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"457_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1365-2796.2012.02588.x","volume":"272","author":"J Marsal","year":"2012","unstructured":"Marsal J, Agace WW. Targeting T-cell migration in inflammatory bowel disease. J Intern Med. 2012;272(5):411\u201329.","journal-title":"J Intern Med"},{"issue":"7","key":"457_CR20","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1080\/08820139.2017.1360343","volume":"46","author":"N Ebrahimi Daryani","year":"2017","unstructured":"Ebrahimi Daryani N, Saghazadeh A, Moossavi S, Sadr M, Shahkarami S, Soltani S, et al. Interleukin-4 and interleukin-10 gene polymorphisms in patients with inflammatory bowel disease. Immunol Invest. 2017;46(7):714\u201329.","journal-title":"Immunol Invest"},{"issue":"3","key":"457_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10157-018-1665-0","volume":"23","author":"J Ruszkowski","year":"2019","unstructured":"Ruszkowski J, Lisowska KA, Pindel M, Heleniak Z, Debska-Slizien A, Witkowski JM. T cells in IgA nephropathy: role in pathogenesis, clinical significance and potential therapeutic target. Clin Exp Nephrol. 2019;23(3):291\u2013303.","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"457_CR22","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.1074\/jbc.M113.512277","volume":"289","author":"H Suzuki","year":"2014","unstructured":"Suzuki H, Raska M, Yamada K, Moldoveanu Z, Julian BA, Wyatt RJ, et al. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J Biol Chem. 2014;289(8):5330\u20139.","journal-title":"J Biol Chem"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00457-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-020-00457-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00457-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:16:07Z","timestamp":1659096967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-020-00457-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["457"],"URL":"https:\/\/doi.org\/10.1007\/s13730-020-00457-x","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,25]]},"assertion":[{"value":"20 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Y. Wada received Speakers Bureau from Mitsubishi Tanabe Pharma Corporation and T. Shibata has received research funding from Mitsubishi Tanabe Pharma Corporation, although the funder played no role in the present case of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was obtained from the patient described in the present case.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}